Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
19.79
+0.04 (0.20%)
At close: Nov 10, 2026, 4:00 PM EST
19.59
-0.20 (-0.99%)
After-hours: Nov 10, 2026, 5:36 PM EST

Silence Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,231287325672547715
Market Cap Growth
296.07%-11.59%-51.64%22.71%-23.44%17.04%
Enterprise Value
1,159185152600448612
Last Close Price
19.796.086.8817.3715.2523.89

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
2001.62513.747.5121.2325.2842.53
PB Ratio
24.304.612.4230.5420.5861.93
P/TBV Ratio
44.115.592.6157.6633.06580.25
P/FCF Ratio
-----96.09
P/OCF Ratio
-----77.58

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
1884.64331.263.5218.9720.6736.40
EV/FCF Ratio
-----82.24

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.000.000.020.020.02
Debt / FCF Ratio
-----0.03
Net Debt / Equity Ratio
-1.87-1.36-1.10-3.11-3.20-8.61
Net Debt / EBITDA Ratio
1.131.043.011.321.681.61
Net Debt / FCF Ratio
1.701.362.171.381.49-13.36
Asset Turnover
0.010.000.270.250.180.14
Quick Ratio
6.408.0610.364.154.035.41
Current Ratio
7.428.7211.144.624.415.69
Return on Equity (ROE)
-90.41%-90.27%-58.08%-223.22%-273.06%-448.22%
Return on Assets (ROA)
-29.65%-30.79%-19.24%-26.32%-26.09%-31.44%
Return on Capital Employed (ROCE)
-68.80%-69.80%-26.70%-54.00%-49.70%-56.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-6.41%-30.86%-13.95%-8.07%-9.20%-7.46%
FCF Yield
-3.43%-21.70%-20.89%-7.37%-10.45%1.04%
Buyback Yield / Dilution
-0.09%-2.12%-24.69%-15.21%-8.58%-8.78%
SEC Filings: 10-K · 10-Q